Percutaneous closure of the appendage: results, evidence, team training.

Our editors talked with Dr. Aníbal Damonte

Percutaneous closure of left atrial appendage is now a practice that is becoming more topical with a view to results and perspectives. In this regard, we interviewed Dr. Aníbal Damonte, interventional cardiologist at the Cardiovascular Institute of Rosario (Rosario, Argentina). 

WEB SOLACI: May I first ask you to explain what is the justification for a procedure such as the closure of the left atrial appendage? 

Aníbal Damonte: Justification for this procedure is based on the high prevalence of atrial fibrillation, which we all know, is the most common cardiac arrhythmia and which in turn is a major cause of morbidity and mortality secondary to cardioembolic stroke rate. 

We have all known for years that the protection strategy for these events rests with oral anticoagulants. However, both experiences in our region, (prospective registry of atrial fibrillation made

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...